Detailed Narrative
Q1 FY27 Financial Performance Highlights
Gujarat Themis Biosyn Limited reported robust financial performance for Q1 FY27. Revenue from operations increased by 22.1% year-on-year to INR 43.8 crores, driven by healthy sales volumes. EBITDA grew by 49.4% year-on-year to INR 20.8 crores, with the EBITDA margin expanding significantly by 867 basis points to 47.5%. Profit after tax also saw a 22.1% year-on-year growth, reaching INR 11.1 crores, demonstrating strong profitability and operational efficiency.
Strategic Transformation to Fermentation-Based CDMO
The company is undergoing a significant strategic transformation to evolve into a larger, more diversified, and innovation-driven fermentation-based CDMO player. This involves expanding fermentation infrastructure, strengthening R&D capabilities, and moving downstream into APIs and other high-value products. Management emphasized that this strategy aims to capture a larger share of the pharmaceutical value chain and build a foundation for sustainable long-term growth.
Key Acquisitions: MicroBiopharm Japan and Sanofi Brands
GTBL is executing two major inorganic growth initiatives. The acquisition of MicroBiopharm Japan will provide access to advanced fermentation technologies, specialized scientific talent, and an established R&D platform, adding new therapy areas like immunosuppressants, oncology, and anti-infectives. Concurrently, the acquisition of 13 established anti-TB and anti-infective brands from Sanofi France will expand GTBL's downstream commercial presence across 55 countries in Europe, Middle East, and Africa. The MicroBiopharm deal is expected to close by August end, while the Sanofi deal is anticipated to close in 6-9 months due to extensive regulatory approvals.
Capacity Expansion and Commercialization
Over the last three years, GTBL has invested approximately INR 370 crores in expanding its gross block, which includes new fermentation and API facilities, R&D infrastructure, and a hybrid power project. The expanded fermentation capacity is now ready, with output expected to contribute to revenue from Q1 FY27 and fully in H2 FY27. The company anticipates a total capex of around INR 20 crores for FY27, primarily for last-mile project completion and maintenance.
Funding Strategy for Acquisitions
The total consideration for the acquisitions is approximately INR 3,000 crores. GTBL plans to fund this through a mix of equity and debt, with plans to raise up to INR 1,000 crores via QIP and secure around INR 2,000 crores in debt. Management noted that the interest costs in the geographies of the acquired entities are lower than typical Indian rates, and the acquired businesses are projected to be cash flow positive from the outset, ensuring financial viability.
Hybrid Power Project and Profitability Improvement
To enhance operational efficiency and improve margins, GTBL is commissioning a hybrid power plant in two phases. Phase 1 is expected to go live in September 2026, followed by Phase 2 two months later. This project is anticipated to significantly reduce power costs, thereby contributing positively to the company's EBITDA margins.
Resolution of Optimus Drugs Dispute
Management confirmed the resolution of a prior dispute with Optimus Drugs, and business operations with them are restarting. The company highlighted that even during the 6-9 month period of non-supply to Optimus, it successfully managed its inventory and maintained full capacity utilization due to sufficient alternative buyers for its products.